Philips provides update on the Annual General Meeting of Shareholders 2025 Agenda
Rhea-AI Summary
Philips (NYSE: PHG) has provided an update regarding its upcoming Annual General Meeting (AGM) scheduled for March 24, 2025. The key focus is on the appointment of Bob White to the Supervisory Board, effective May 8, 2025.
Following White's nomination as CEO at Olympus , there has been a modification to his planned role at Philips. While he will still join the Quality & Regulatory (Q&R) Committee, he will no longer serve as its chair. Dr Paul Stoffels will instead chair the Q&R Committee, while Herna Verhagen will succeed Stoffels as chair of the Remuneration Committee.
White's dual positions at Philips and Olympus will align with proxy advisor guidelines, consisting of one non-executive and one executive position at publicly listed companies.
Positive
- Appointment of experienced health technology executive Bob White to Supervisory Board
- Maintenance of strong corporate governance with immediate committee chair replacements
Negative
- Modification of planned leadership structure for Q&R Committee due to White's competing commitments
News Market Reaction – PHG
On the day this news was published, PHG gained 1.25%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
April 25, 2025
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) provides an update on the Annual General Meeting 2025 which has been convened on March 24, 2025 (AGM).
As previously announced, the AGM agenda includes the proposal to appoint Mr Bob White (American, 1962) as a new member of the Supervisory Board, with effect from May 8, 2025, given his extensive expertise and experience in health technology and quality.
Since the company published the agenda for the AGM, Mr White has been nominated to become Chief Executive Officer at Olympus Corporation and has informed the company that in view of this nomination and his nomination at Philips, he will step down from other board positions he currently holds.
In light hereof, the Supervisory Board and Mr White have agreed that he will become a member of Philips’ Quality & Regulatory (Q&R) Committee but that he will not be acting as its chair as was previously communicated.
Following shareholders’ approval of all proposals in respect of the Supervisory Board composition at the AGM, Dr Paul Stoffels will become chair of the Q&R Committee of the Supervisory Board, and Mrs Herna Verhagen will succeed Dr Paul Stoffels as chair of its Remuneration Committee.
Following his appointments at Philips and Olympus, Mr White will hold one non-executive and one executive position at publicly listed companies in line with current guidelines from proxy advisors on directors’ external commitments.
For further information, please contact:
Michael Fuchs
Philips Global External Relations
Tel.: +31 61486 9261
E-mail: media@philips.com
Dorin Danu
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: dorin.danu@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Forward-looking statements and other important information
This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.
FAQ
When is Philips (PHG) holding its Annual General Meeting 2025?
Who is being appointed to Philips' (PHG) Supervisory Board in 2025?
What changes were made to Bob White's role on Philips' (PHG) committees?
Who will chair Philips' (PHG) Quality & Regulatory Committee after the 2025 AGM?
